Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observational study of henggliflozin safety and efficacy in Chinese adults with type 2 diabetes
ChiCTR2500102967Phase 4Not yet recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of henagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoint: Adverse events or serious adverse events. Planned start May 2025; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500102967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102967.